

FGFR4 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7639A

Product Information

Application FC, IHC-P, WB, E

Primary Accession P22455

Reactivity Human, Rat, Mouse

HostRabbitClonalityPolyclonalIsotypeRabbit IgGCalculated MW87954Antigen Region24-55

Additional Information

Gene ID 2264

Other Names Fibroblast growth factor receptor 4, FGFR-4, CD334, FGFR4, JTK2, TKF

Target/Specificity This FGFR4 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 24-55 amino acids from the N-terminal

region of human FGFR4.

Dilution FC~~1:10~50 IHC-P~~1:100~500 WB~~1:1000 E~~Use at an assay dependent

concentration.

Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is purified through a protein G column, followed by dialysis

against PBS.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions FGFR4 Antibody (N-term) is for research use only and not for use in diagnostic

or therapeutic procedures.

Protein Information

Name FGFR4

Synonyms JTK2, TKF

Function Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast

growth factors and plays a role in the regulation of cell proliferation,

differentiation and migration, and in regulation of lipid metabolism, bile acid

biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down- regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

Cellular Location

Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane

Tissue Location

Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines

Background

FGFR4 is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of the gene, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the IgIII domain of this protein varies between three alternate forms, as indicated for members 1-3. This particular family member preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis.

References

References for protein:

1. Jezeguel, P., et al., Br. J. Cancer 90(1):189-193 (2004).

2. Oian, Z.R., et al., J. Clin. Endocrinol. Metab. 89(4):1904-1911 (2004).

3.Yu, S., et al., J. Biol. Chem. 278(22):19597-19602 (2003).

4.Becker, N., et al., Cancer Epidemiol. Biomarkers Prev. 12(6):582-583 (2003).


5.Takenaka, H., et al., Arch. Dermatol. Res. 294(7):331-338 (2002).

References for HeLa cell line:


- 1. Scherer WF, Syverton JT, Gey GO (May 1953). "Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix". J. Exp. Med. 97 (5): 695–710. [PubMed:13052828].
- 2. Macville M, Schr Ek E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T (January 1999). "Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping". Cancer Res. 59 (1): 141–50. [PubMed: 9892199].
- 3. Rahbari R, Sheahan T, Modes V, Collier P, Macfarlane C, Badge RM (April 2009). "A novel L1 retrotransposon marker for HeLa cell line identification". BioTechniques 46 (4): 277–84. [PubMed: 19450234].

4. Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR, Freshney RI (July 2010). "Check your cultures! A list of cross-contaminated or misidentified cell lines". Int. J. Cancer 127 (1): 1–8. [PubMed:20143388].

Images



Flow cytometric analysis of WiDr cells using FGFR4 Antibody (N-term) (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.